No golden signals this cycle (RSI<30 + insider buying) — CRSP is the closest, cooling out of overbought territory (RSI 69.6→45.8) with genuine insider buying stacked on top, but its structure is still death-crossed. The prior scan's biotech-overbought cluster (MRNA, VRTX, NTLA, CRSP, all RSI 70-82) cooled dramatically across the board — a real price pullback this time, not just RSI compression. Insider buying stays thin: only TSLA, CRSP, and ASAN show net buying (three names, versus 54 with net selling), and none of that buying sits inside intact technical structure. EOSE is the single most oversold name in the universe (RSI 29.6) but shows no insider-buying confirmation — a technical extreme, not a signal.

Data as-of 2026-07-10 close. Source: the desk's own tooling (live insider Form-4 net dollars) cross-referenced against summaries/insider-universe.json for price/RSI/structure — CLI prices matched the summary exactly on every name checked, no discrepancy correction needed. Prior scan: 2026-07-07-insider-scan.

Insider buying stays scarce: only TSLA (+$205.3M net), CRSP (+$28.1M), and ASAN (+$8.4M) show net insider accumulation, and none of the three sits inside clean technical structure. TSLA is death-crossed and merely pullback (RSI 51.5, -2.5% vs SMA200); CRSP is death-crossed and downtrend (RSI 45.8, -3.9% vs SMA200) despite a real biotech-sector cooldown; ASAN is death-crossed and downtrend, still -53.3% off its 52-week high. None of this buying is a green light on its own — it's a data point to weigh against damaged charts, not a signal to act on.

Selling is broad — 54 of 59 tracked names show net insider selling, led by mega-caps (AMZN -$9.2B, NVDA -$3.3B, LLY -$3.1B) whose dollar totals are large mostly because of company size, not necessarily a bearish tell. The more useful cut is selling paired with damaged structure: PLTR (-$2.5B net, RSI 48.4, deathCross, downtrend, -19.1% vs SMA200) and NFLX (-$1.4B net, RSI 37.5, deathCross, collapse, -22.7% vs SMA200) both combine heavy selling with broken charts — that combination calls for outside verification before treating either as attractive on price alone. By contrast, DOCN (-$673.7M net, RSI 38.9, but goldenCross still intact, pullback, +60.9% vs SMA200) is a case of heavy selling inside a technically-intact uptrend — worth a name-level look at why insiders are selling into what is still a structurally healthy chart.

The biggest move since the last scan is the biotech-overbought cluster cooling off. MRNA, VRTX, NTLA, and CRSP were all RSI 70-82 last scan; all four have since cooled to the mid-40s-to-mid-50s, and unlike the ETF-sleeve cooldown seen elsewhere in this corpus, this one came with real price declines (MRNA -16.5%, NTLA -20.3%), not just RSI compression through time. EOSE remains the single most oversold name in the tracked universe at RSI 29.6, collapse regime, -58.2% vs SMA200 — but it shows no insider-buying confirmation, so per desk doctrine this is a technical extreme to watch, not a buy signal.

This is a price-and-structure screen cross-referenced with live insider Form-4 net dollars — not a recommendation engine. "Insider buying" flags net accumulation; it says nothing about whether the chart is worth owning. A low RSI paired with insider buying is only a genuine "golden" signal below RSI 30 — everything else is a data point to weigh, not a trigger. Heavy insider selling on a mega-cap is frequently routine (compensation-driven, diversification) and should not be read as bearish without checking the filing detail; heavy selling on a name that's also technically damaged (deathCross, downtrend/collapse regime) is the pairing worth flagging for outside verification. Structure labels — intact (goldenCross, uptrend/basing), damaged (deathCross, downtrend/collapse), extended (large positive vs SMA200 in an uptrend) — describe the chart only.

(34 more names carry net insider selling below the top-20 cut shown above, including NTLA, UI, CEG, BNTX, INTC, TSM, ENPH, MRNA, AKAM, EOSE — none flagged "selling into dip.")

(23 remaining tracked names — ISRG, MRVL, QCOM, GOOGL, CRM, MSFT, ARM, ZS, ASML, MDB, UBER, NOW, FSLY, HIMS, IBKR, CRWD, SHOP, FTNT, PINS, AFRM, U, TMO, META — sit at RSI 45-66, basing/steady, no insider-buy or heavy-selling flag surfaced by the CLI's top cuts this cycle.)

Buying, but not clean — TSLA/CRSP/ASAN are the only net-buying names, and all three carry deathCross/downtrend tags. CRSP is the most interesting: it just cooled out of a biotech-overbought extreme (RSI 69.6→45.8) with genuine insider accumulation on top — worth a name-level follow-up if a golden cross prints next scan.

Heavy selling, intact structure — AMZN, NVDA, LLY, AVGO, PANW, SNOW, ABNB, NET, DOCN, DDOG, TWLO, BE, AAPL, AMD all show large insider selling dollars but sit inside intact (goldenCross) technical structure. Read this as scale-driven (mega-cap compensation/diversification programs), not a bearish tell on its own.

Heavy selling, damaged structure — verification-worthy — PLTR (-$2.5B) and NFLX (-$1.4B) pair large insider selling with deathCross/downtrend-or-collapse charts. This is the combination the desk should actually verify before any accumulate call, not the mega-cap selling above.

Biotech cluster cooled hard — MRNA, VRTX, NTLA, CRSP all dropped from RSI 70-82 to the mid-40s-to-mid-50s with real price pullbacks (MRNA -16.5%, NTLA -20.3%). Confirms the sector-wide overbought read from the 2026-06-26 monster scan is finally resolving via price, not just time.

Technical extremes without confirmation — EOSE (RSI 29.6) is the single most oversold name in the universe but carries no insider-buying signal; per desk doctrine, a low RSI alone inside this tracked universe is not a recommendation.